Aspirin, metformin, and statins were independently associated with decreased lung cancer mortality, according to a population-based study.
This was a planned interim analysis of a phase 3 study comparing lorlatinib and crizotinib as a frontline treatment for patients with ALK-positive NSCLC.
Analysis suggests osimertinib lowers the risk of CNS recurrence in patients with completely resected EGFR-mutated NSCLC.
Capmatinib showed clinical activity in patients with MET exon 14–mutated advanced non–small cell lung cancer, reported a phase 2 trial.
An analysis finds that mortality rates for NSCLC are falling faster than incidence rates, which the authors attributed to the introduction of targeted therapies in 2013.
Expertscape, a platform for discovering physicians excelling in the treatment and diagnosis of specific disease states, has released their rankings for US physicians who specialize in lung cancer. Using Expertscape’s patented algorithm, Suresh Ramalingham, MD, of Emory University in Atlanta, Georgia, topped the list. Among his many publications in 2020, Ramalingham published a paper on…
Nurses working in primary care settings are well-situated to identify and educate patients at high risk of lung cancer who are eligible to undergo LDCT screening.
The FDA has approved Gavreto™ (pralsetinib; Blueprint Medicines and Genentech) for the treatment of adults with metastatic RET fusion-positive NSCLC.
Although PFS was similar with both agents, a single-center retrospective comparative analysis found that pembrolizumab was associated with a higher ORR vs nivolumab in NSCLC.
NSCLC harboring SMARCA4 alterations without STK11/KEAP1 mutations was not associated with poor outcomes with ICI treatment in a retrospective study.
Researchers suggest a less-is-more approach may be better than relying on “big data” when deciding on treatment at point of care.
CXR-LC model had better discrimination than CMS eligibility, similar performance to PLCO Model 2012.
Using a blood sample, the test is able to analyze more than 300 cancer-associated genes for alterations.
Tepotinib is an oral MET inhibitor designed to inhibit the oncogenic MET receptor signaling caused by MET (gene) alterations.
Patients with ALK-positive advanced non-small cell lung cancer who received brigatinib lived longer progression-free compared with patients who received crizotinib.
Real-world data from Flatiron Health/Foundation Medicine database were used to compare the outcomes of patients with advanced NSCLC who were treated with targeted therapies.
Historical trend of increased incidence in Blacks versus Whites disappeared in men, reversed in women.
A study reveals that 2.4% of patients developed DILD with a median time to onset of 63 days.
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.